# CREB1 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - CREB1 is a ubiquitous transcription factor that integrates multiple signaling pathways (cAMP/PKA, CaMK, MAPK) to regulate genes involved in cellular proliferation, differentiation, survival, and memory formation, binding to the CRE consensus sequence (TGACGTCA). - Its activity is tightly regulated by phosphorylation at Ser133, which promotes recruitment of coactivators CBP/p300, and is further modulated by alternative splicing generating isoforms with varying transactivation potential. - Dysregulation of CREB1, through genetic variants or somatic mutations, is implicated in a broad spectrum of diseases including neuropsychiatric disorders (MDD, BD, schizophrenia), neurodegenerative conditions (Alzheimer's, Huntington's), and various malignancies. - Recurrent chromosomal translocations, notably EWSR1-CREB1 fusions, are pathognomonic for rare mesenchymal tumors like angiomatoid fibrous histiocytoma (AFH) and primary pulmonary myxoid sarcoma (PPMS). - CREB1 plays a critical role in viral interactions, with its activation by ALVAC vaccination enhancing immunogenicity against HIV-1, and is involved in host immune responses and evasion mechanisms in bacterial infections and cancer. - Altered CREB1 expression and activity are implicated in non-neoplastic diseases such as osteoarthritis, liver fibrosis, and vascular dementia, suggesting its broader therapeutic potential beyond oncology. --- ## Executive Summary & Key Metadata The **CREB1** (cAMP responsive element binding protein 1) gene encodes a ubiquitous, constitutively expressed nuclear transcription factor that serves as a master integrator of multiple intracellular signaling cascades. As a member of the ATF/CREB family of basic leucine zipper (bZIP) transcription factors, CREB1 binds to the cyclic AMP response element (CRE) consensus sequence (TGACGTCA) within the promoter/enhancer regions of target genes, thereby modulating transcriptional programs governing cellular proliferation, differentiation, survival, metabolism, memory formation, and immune responses. Its activity is exquisitely regulated by phosphorylation at a critical serine residue (Ser133), which promotes recruitment of the coactivator paralogs CREB-binding protein (CBP) and p300, linking CREB1 to the basal transcriptional machinery. Beyond its canonical role in the cAMP/protein kinase A (PKA) pathway, CREB1 is a convergence point for calcium/calmodulin-dependent kinases (CaMKs), mitogen-activated protein kinases (MAPKs), and stress-activated signaling pathways, making it a central node in cellular adaptation and plasticity. Dysregulation of CREB1—through genetic polymorphism, somatic mutation, gene fusion, or epigenetic alteration—is implicated in a broad spectrum of human pathologies, including neuropsychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia), neurodegenerative conditions (Alzheimer's disease, Huntington's disease), and a diverse array of malignancies (breast, colorectal, gastric, prostate, thyroid, and soft-tissue sarcomas). Notably, recurrent chromosomal translocations fusing the *EWSR1* gene to *CREB1* are pathognomonic for several rare mesenchymal tumors, including angiomatoid fibrous histiocytoma (AFH) and primary pulmonary myxoid sarcoma (PPMS). The following table summarizes the key metadata for the human *CREB1* gene. | **Attribute** | **Value** | |:---|:---| | **HGNC Symbol** | CREB1 | | **UniProt Accession** | P16220 | | **Representative PDB ID** | 1DH3 (bZIP domain with DNA) | | **Chromosomal Locus** | 2q33.3 (GRCh38: chr2:207,529,961-207,605,951) | | **Primary Molecular Function** | cAMP-responsive transcription factor; sequence-specific DNA binding; transcription coactivator recruitment | | **Disease & Pathology Associations** | Major depressive disorder, bipolar disorder, schizophrenia, Alzheimer's disease, Huntington's disease, angiomatoid fibrous histiocytoma, primary pulmonary myxoid sarcoma, breast cancer, colorectal cancer, prostate cancer, gastric cancer, thyroid cancer, osteoarthritis, multiple myeloma | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human *CREB1* gene is located on the long arm of chromosome 2 at cytogenetic band **2q33.3**. The reference genome assembly (GRCh38) places the gene between coordinates 207,529,961 and 207,605,951 on the forward strand, spanning approximately 76 kilobases (kb) of genomic DNA. The gene comprises **11 exons** and **10 introns**, with the translation initiation codon located in exon 1 and the termination codon in exon 11. The genomic architecture is complex, featuring multiple alternative promoters, extensive alternative splicing, and several regulatory elements distributed across the locus. The *CREB1* locus is embedded within a gene-dense region of chromosome 2q, flanked by several other genes, including *PDE1B* (phosphodiesterase 1B) and *C2orf47*. The 3' region of *CREB1* overlaps with the *SART3* (squamous cell carcinoma antigen recognized by T cells 3) gene in a head-to-head (bidirectional) configuration, sharing a bidirectional promoter that regulates the expression of both genes. This bidirectional promoter architecture is functionally significant, as single nucleotide polymorphisms (SNPs) within this region can simultaneously affect the transcription of both *CREB1* and *SART3*. A specific SNP, rs2072580 (T→A), located within this bidirectional promoter, has been demonstrated to disrupt the CREB1 binding site, thereby altering the transcriptional activity of both genes. ### 1.2 Promoter Architecture and Regulatory Elements The *CREB1* gene is regulated by at least two distinct promoters: a proximal promoter (P1) and a distal promoter (P2), which drive the expression of different transcript variants. The proximal promoter (P1) is located immediately upstream of exon 1 and contains a canonical TATA box, multiple Sp1 binding sites, and several CRE half-sites that permit autoregulation by CREB1 itself. The distal promoter (P2) is located further upstream and is GC-rich, lacking a canonical TATA box but containing multiple CpG dinucleotides that are subject to DNA methylation-dependent regulation. The promoter region of *CREB1* is characterized by a high density of transcription factor binding sites (TFBSs), including consensus motifs for AP-1, AP-2, NF-κB, and C/EBP family members. This regulatory complexity allows *CREB1* expression to be modulated by a wide array of extracellular stimuli, including growth factors, cytokines, neurotransmitters, and hormones. The promoter also contains several estrogen response elements (EREs), which partially explain the sex-specific differences observed in *CREB1* expression and its differential association with depressive disorders in women. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of the *CREB1* primary transcript generates multiple mRNA isoforms that encode distinct protein variants with differential transcriptional activities. The major isoforms are: - **CREB1α (full-length, 341 amino acids)**: The canonical isoform, containing all functional domains (Q1, KID, Q2, bZIP). This isoform is the most abundant and is the primary mediator of cAMP-responsive transcription. - **CREB1β (327 amino acids)**: Lacks a 14-amino acid segment within the Q1 domain due to alternative splicing of exon 4. This isoform exhibits reduced transactivation potential compared to CREB1α. - **CREB1Δ (327 amino acids)**: Lacks a 14-amino acid segment within the Q2 domain due to alternative splicing of exon 6. This isoform has a dominant-negative effect, as it can dimerize with wild-type CREB1 but fails to recruit CBP/p300 effectively. - **CREB1ω (309 amino acids)**: A truncated isoform lacking the bZIP domain, generated by alternative splicing that introduces a premature stop codon. This isoform is predominantly cytoplasmic and may exert dominant-negative effects by sequestering coactivators. The relative expression of these isoforms is tissue-specific and developmentally regulated. For instance, the CREB1Δ isoform is highly expressed in the brain during early development but is downregulated in adulthood, suggesting a role in neurodevelopmental processes. The alternative splicing of *CREB1* is itself regulated by neuronal activity and cellular stress, adding another layer of complexity to its functional regulation. ### 1.4 Epigenetic Regulation The *CREB1* locus is subject to extensive epigenetic regulation. DNA methylation at CpG islands within the promoter regions correlates inversely with *CREB1* expression. Hypermethylation of the *CREB1* promoter has been observed in several cancer types, leading to transcriptional silencing and contributing to tumor progression. Conversely, histone acetylation at the *CREB1* promoter, mediated by histone acetyltransferases (HATs) such as CBP/p300, is associated with transcriptional activation. The interplay between DNA methylation and histone modification at the *CREB1* locus is particularly important in the context of neuropsychiatric disorders, where environmental factors such as early-life stress can induce lasting epigenetic changes that alter *CREB1* expression and contribute to disease susceptibility. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The human CREB1 protein (UniProt P16220) is a 341-amino acid polypeptide with a molecular weight of approximately 36.7 kDa. The protein is organized into several functionally distinct domains, arranged from the N-terminus to the C-terminus as follows: | **Domain** | **Residues (approx.)** | **Function** | |:---|:---|:---| | **Q1 (Glutamine-rich) domain** | 1–100 | Constitutive transactivation domain; mediates interactions with TAFII130 and other basal transcription factors | | **KID (Kinase-Inducible Domain)** | 100–160 | Regulatory domain containing the critical Ser133 phosphorylation site; undergoes induced folding upon binding to CBP/p300 | | **Q2 (Glutamine-rich) domain** | 160–280 | Constitutive transactivation domain; primary interaction surface for CBP/p300 KIX domain | | **bZIP (basic Leucine Zipper) domain** | 280–341 | DNA-binding and dimerization domain; mediates sequence-specific binding to CRE and homo/heterodimerization with other bZIP family members | ### 2.2 The Kinase-Inducible Domain (KID) and Ser133 Phosphorylation The KID domain (residues 100–160) is the central regulatory module of CREB1. This domain is intrinsically disordered in its unphosphorylated state but undergoes a disorder-to-order transition upon phosphorylation at Ser133. The phosphorylation of Ser133 is catalyzed by multiple kinases, including PKA, CaMKIV, RSK2, MSK1, and MAPKAP-K2, depending on the upstream signaling pathway activated. Phosphorylated Ser133 (pSer133) creates a high-affinity docking site for the KIX domain of the transcriptional coactivators CBP and p300. The KID-KIX interaction is characterized by a dissociation constant (Kd) of approximately 1–10 μM for the unphosphorylated state, which decreases to approximately 100 nM upon phosphorylation, representing a ~10- to 100-fold increase in binding affinity. The structural basis for this phosphorylation-dependent binding has been elucidated by NMR spectroscopy and X-ray crystallography. The pKID domain adopts a helix-loop-helix conformation upon binding to the KIX domain, with pSer133 forming critical hydrogen bonds and electrostatic interactions with conserved residues in the KIX domain (notably Tyr658 and Lys662 in CBP). This induced-fit mechanism ensures that CREB1-mediated transcription is tightly coupled to the activation state of upstream signaling pathways. ### 2.3 The bZIP Domain and DNA Binding The C-terminal bZIP domain (residues 280–341) mediates both sequence-specific DNA binding and protein dimerization. The domain consists of two subregions: 1. **Basic region (residues 280–300)**: Rich in basic amino acids (arginine and lysine), this region directly contacts the major groove of DNA at the CRE consensus sequence (TGACGTCA). The basic region adopts an α-helical conformation upon DNA binding, with specific residues (Arg301, Arg306, Lys309) forming direct hydrogen bonds with the guanine and cytosine bases of the CRE. 2. **Leucine zipper region (residues 301–341)**: Contains four heptad repeats of leucine residues (Leu311, Leu318, Leu325, Leu332) that form a coiled-coil structure mediating dimerization. The leucine zipper allows CREB1 to form both homodimers and heterodimers with other bZIP family members, including ATF1, CREM, and c-Jun. Heterodimerization expands the repertoire of DNA sequences that CREB1-containing complexes can bind, contributing to the functional diversity of CREB1-mediated transcription. The crystal structure of the CREB1 bZIP domain bound to a CRE-containing DNA duplex (PDB: 1DH3) reveals that the two α-helices of the dimer cross the major groove in a scissors-like fashion, with the basic regions making base-specific contacts and the leucine zipper forming a parallel coiled-coil that stabilizes the dimer. The DNA is slightly bent (~20°) upon CREB1 binding, which may facilitate the recruitment of additional transcriptional regulators. ### 2.4 Post-Translational Modifications Beyond Ser133 phosphorylation, CREB1 is subject to multiple other post-translational modifications that modulate its activity: - **Phosphorylation at Ser108, Ser111, Ser114, Ser117, Ser121, Ser129, Ser142, and Ser143**: These additional phosphorylation sites within the KID domain and adjacent regions can either enhance or inhibit CREB1 transcriptional activity. For example, phosphorylation at Ser142 by CaMKII inhibits CREB1-mediated transcription by disrupting the KID-KIX interaction, providing a mechanism for signal-dependent negative regulation. - **Acetylation at Lys91, Lys94, Lys136, and Lys285**: Acetylation by CBP/p300 or SIRT1 can modulate CREB1 DNA binding and transcriptional activity. - **Ubiquitination and SUMOylation**: CREB1 is subject to ubiquitin-mediated proteasomal degradation, and SUMOylation at Lys285 has been shown to regulate its transcriptional activity and subcellular localization. - **ISGylation**: Recent studies have demonstrated that CREB1 can be modified by ISG15 (interferon-stimulated gene 15) through a process termed ISGylation. ISGylation of CREB1 at specific lysine residues enhances its stability and transcriptional activity, and dysregulation of this modification contributes to liver fibrosis. ### 2.5 Interactive 3D Visualization To explore the three-dimensional structure of CREB1 and its interaction with DNA and coactivators, the following interactive visualizer can be used: [Interactive 3D Protein Visualizer: Load CREB1 (PDB: 1DH3)](/tools/protein-structure-viewer?source=alphafold&accession=P16220) This tool allows users to rotate, zoom, and inspect the atomic coordinates of the CREB1 bZIP domain in complex with its cognate DNA response element, as well as to visualize the KID domain in its phosphorylated and unphosphorylated states. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Canonical cAMP/PKA/CREB1 Signaling Pathway The most well-characterized signaling pathway leading to CREB1 activation is the G-protein-coupled receptor (GPCR)-mediated cAMP/PKA pathway. The cascade is initiated by the binding of extracellular ligands (e.g., catecholamines, glucagon, ACTH, and various neuropeptides) to GPCRs coupled to the stimulatory G protein Gαs. Activation of Gαs stimulates adenylyl cyclase, which catalyzes the conversion of ATP to cyclic AMP (cAMP). Elevated intracellular cAMP levels activate PKA by binding to its regulatory subunits, causing dissociation and release of the catalytic subunits. The free catalytic subunits translocate to the nucleus, where they phosphorylate CREB1 at Ser133. Phosphorylated CREB1 (pCREB1) then recruits the coactivators CBP and p300 via their KIX domains. CBP/p300 possess intrinsic histone acetyltransferase (HAT) activity, which acetylates histone tails at target gene promoters, leading to chromatin decondensation and transcriptional activation. Additionally, CBP/p300 interact with RNA polymerase II and the basal transcription machinery, facilitating the assembly of the pre-initiation complex and promoting transcriptional elongation. ### 3.2 Calcium-Dependent CREB1 Activation In addition to the cAMP pathway, CREB1 is activated by calcium (Ca²⁺) signaling, which is critical for neuronal function and synaptic plasticity. Voltage-gated calcium channels and NMDA-type glutamate receptors mediate Ca²⁺ influx into neurons, leading to the activation of Ca²⁺/calmodulin-dependent protein kinases (CaMKs), particularly CaMKIV. CaMKIV phosphorylates CREB1 at Ser133, promoting CREB1-dependent transcription of immediate-early genes and genes involved in long-term potentiation (LTP) and memory formation. The Ca²⁺/calmodulin-dependent phosphatase calcineurin can dephosphorylate CREB1, providing a negative feedback mechanism that limits the duration of CREB1 activation. ### 3.3 MAPK/ERK and Stress-Activated Pathways CREB1 is also a downstream target of the Ras/Raf/MEK/ERK signaling cascade. Growth factors and neurotrophins (e.g., BDNF, NGF) activate receptor tyrosine kinases (RTKs), which initiate the MAPK cascade. ERK1/2 phosphorylates the ribosomal S6 kinase RSK2, which in turn phosphorylates CREB1 at Ser133. This pathway is particularly important for neurotrophin-mediated neuronal survival and differentiation. Additionally, stress-activated protein kinases, including p38 MAPK and JNK, can phosphorylate CREB1 at Ser133 via downstream kinases such as MSK1 and MAPKAP-K2, linking cellular stress responses to CREB1-dependent transcriptional programs. ### 3.4 Non-Canonical CREB1 Signaling and CRTC Coactivators Recent studies have revealed that CREB1-mediated transcription is not solely dependent on Ser133 phosphorylation. The CREB-regulated transcription coactivators (CRTCs), particularly CRTC1, CRTC2, and CRTC3, represent a family of coactivators that bind to the bZIP domain of CREB1 independently of Ser133 phosphorylation. Under basal conditions, CRTCs are sequestered in the cytoplasm by 14-3-3 proteins. Upon cAMP elevation or calcium influx, CRTCs are dephosphorylated by calcineurin, leading to their nuclear translocation and binding to CREB1. The CRTC-CREB1 interaction promotes the recruitment of TAFII130 and other components of the basal transcription machinery, driving robust transcriptional activation. The relative contribution of pCREB1-CBP versus CRTC-dependent pathways varies across cell types and stimuli. In some contexts, CRTC-mediated transcription is the dominant mechanism for cAMP-induced gene expression, while in others, pCREB1-CBP is required. This functional redundancy provides robustness to CREB1-dependent transcriptional programs and allows for cell-type-specific responses to extracellular signals. ### 3.5 CREB1 Target Genes and Transcriptional Networks CREB1 regulates the expression of a large and diverse set of target genes, estimated to comprise 4,000–10,000 loci in the human genome. These target genes can be broadly categorized into: - **Immediate-early genes**: *FOS*, *JUN*, *EGR1*, *NR4A1*, which are rapidly induced in response to extracellular stimuli and function as secondary transcription factors. - **Neuroplasticity and memory-related genes**: *BDNF*, *ARC*, *SYN1*, *DNM1*, *STX1*, which are critical for synaptic plasticity, LTP, and long-term memory formation. - **Metabolic genes**: *PEPCK*, *G6Pase*, *MDH2*, which regulate gluconeogenesis, mitochondrial metabolism, and energy homeostasis. - **Cell cycle and proliferation genes**: *CCNA2*, *CCND1*, *MYC*, which promote cell cycle progression and proliferation. - **Differentiation genes**: *MYOG*, *SOX9*, *ETV2*, which drive lineage-specific differentiation programs. - **Immune and inflammatory genes**: *CCL2*, *CCL20*, *HLA-E*, which modulate immune responses and tumor immune evasion. - **Anti-oxidant and stress response genes**: *GPX4*, *NRF2*, which protect cells from oxidative stress. The transcriptional networks regulated by CREB1 are highly context-dependent, with the specific set of target genes activated depending on the cell type, the nature of the stimulus, and the availability of coactivators and chromatin modifiers. ### 3.6 Protein-Protein Interaction Networks CREB1 participates in extensive protein-protein interaction networks, as cataloged in databases such as BioGRID and STRING. Key interaction partners include: - **Transcriptional coactivators**: CBP, p300, CRTC1/2/3, TAFII130 - **Transcriptional corepressors**: HDAC1, SIN3A, NCOR1 - **Kinases**: PKA catalytic subunit, CaMKIV, RSK2, MSK1, MAPKAP-K2 - **Phosphatases**: PP1, PP2A, calcineurin - **Transcription factors**: ATF1, CREM, c-Jun, c-Fos, MEF2C, MYOD1, MESP1, CEBPB - **Chromatin remodelers**: BRG1, CHD1 - **E3 ubiquitin ligases and modifiers**: CUL5, ISG15 These interactions position CREB1 as a central hub in cellular signaling networks, integrating inputs from multiple pathways and coordinating transcriptional outputs across diverse biological processes. ### 3.7 CREB1 in Development and Differentiation CREB1 plays essential roles in embryonic development and cellular differentiation. In the cardiovascular system, CREB1 interacts with MESP1 to coactivate the expression of *ETV2*, a master regulator of endothelial and hematopoietic development. In skeletal muscle, CREB1 cooperates with MYOD1 and MEF2C to regulate the expression of muscle-specific genes, including *TCEAL7* and *NCAPG*, promoting myoblast proliferation and differentiation. In the reproductive system, CREB1 regulates the expression of *SOX9* in Sertoli cells, which is critical for testicular development and spermatogenesis. In the female reproductive tract, CREB1 mediates progesterone and cAMP signaling during uterine stromal decidualization, a prerequisite for embryo implantation. In the nervous system, CREB1 is required for the differentiation and survival of neurons, and its activity is essential for activity-dependent gene expression underlying learning and memory. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Polymorphisms and Neuropsychiatric Disorders The *CREB1* gene harbors numerous common genetic variants (SNPs) that have been associated with susceptibility to neuropsychiatric disorders. These variants are typically located in non-coding regions (introns, promoters, 3' UTR) and are thought to exert their effects by modulating *CREB1* expression levels or splicing patterns. **Major Depressive Disorder (MDD)**: Multiple studies have reported associations between *CREB1* SNPs and MDD susceptibility. A study by Ma et al. (2017) demonstrated that the combination of *GNB3* and *CREB1* gene polymorphisms with negative life events significantly increased susceptibility to major depression in a Chinese Han population. Similarly, Wang et al. (2015) found that *CREB1* gene polymorphisms combined with environmental risk factors increased susceptibility to MDD. The sex-specific linkage of the *CREB1*-containing region on chromosome 2q33-35 to depressive disorders in women from families with recurrent, early-onset major depression has been confirmed in multiple studies. Furthermore, *CREB1* SNPs have been associated with cognitive dysfunction in Chinese patients with major depression and with treatment resistance in major depression. **Bipolar Disorder (BD)**: Common variants in *CREB1* confer risk for bipolar disorder in Han Chinese populations. A comprehensive study by Li et al. (2013) identified significant allelic differences between Europeans and Chinese for *CREB1* SNPs, which have implications for gene expression regulation, hippocampal structure and function, and bipolar disorder susceptibility. These findings highlight the importance of population-specific genetic architecture in psychiatric genetics. **Schizophrenia**: Gene expression meta-analysis has revealed the up-regulation of *CREB1* and *CREBBP* in Brodmann Area 10 of patients with schizophrenia, suggesting that altered CREB1 signaling contributes to the cognitive impairments characteristic of this disorder. **Other Psychiatric and Neurological Conditions**: *CREB1* polymorphisms have been associated with: - Prospective memory performance in healthy cohorts (rs2253206) - Drug-seeking behavior in eastern Indian addicts - Aggression among male Chinese adolescents, with gene-environment interactions with childhood maltreatment - Panic disorder and early treatment response to escitalopram - Fibromyalgia (in combination with *BDNF*, *NTRK2*, and other genes) - Geriatric insomnia - Alzheimer's disease (copy number variations and expression changes) - Huntington's disease (altered CREB1 pathway in white adipose tissue) ### 4.2 Somatic Mutations and Gene Fusions in Cancer **EWSR1-CREB1 Gene Fusions**: The most clinically significant genetic alteration involving *CREB1* in cancer is the recurrent chromosomal translocation t(2;22)(q33;q12), which fuses the *EWSR1* gene (22q12) with *CREB1* (2q33). This fusion generates a chimeric oncoprotein consisting of the N-terminal transactivation domain of EWSR1 and the C-terminal bZIP DNA-binding domain of CREB1. The EWSR1-CREB1 fusion protein acts as an aberrant transcription factor that drives the expression of genes involved in cell proliferation, survival, and migration. The EWSR1-CREB1 fusion is pathognomonic for several rare mesenchymal tumors: 1. **Angiomatoid Fibrous Histiocytoma (AFH)**: AFH is a rare soft tissue tumor of intermediate malignant potential, most commonly occurring in the subcutaneous tissue of the extremities in children and young adults. The EWSR1-CREB1 fusion is present in the majority of AFH cases, with variant fusions involving *EWSR1-ATF1* occurring less frequently. AFH can occasionally metastasize, and unusual presentations have been reported, including primary lung and rib involvement with systemic multiple metastases, intracranial non-myxoid AFH, and pleomorphic variants associated with multiplication of the fusion gene. 2. **Primary Pulmonary Myxoid Sarcoma (PPMS)**: PPMS is an extremely rare malignant pulmonary neoplasm characterized by the t(2;22)(q33;q12) translocation resulting in EWSR1-CREB1 fusion. PPMS typically presents as an endobronchial or intrapulmonary mass with a myxoid stroma and a lobulated growth pattern. The tumor can resemble extraskeletal myxoid chondrosarcoma (EMC) histologically, making molecular confirmation essential for accurate diagnosis. Unusual variants include intraluminal growth within the pulmonary artery and fusions between exon 7 of *EWSR1* and exon 5 of *CREB1*. 3. **Intracranial Myxoid Mesenchymal Tumors**: EWSR1-CREB1 fusions have been identified in intracranial myxoid mesenchymal tumors, a rare group of primary central nervous system neoplasms. These tumors can occur in the brain parenchyma or ventricles and exhibit a myxoid morphology with variable cellularity. The clinical behavior ranges from benign to malignant, and surgical resection is the primary treatment modality. 4. **Clear Cell Odontogenic Carcinoma (CCOC)**: EWSR1-CREB1 has been identified as an alternative fusion gene to EWSR1-ATF1 in CCOC, a rare malignant odontogenic tumor of the jaws. 5. **Other Tumors**: EWSR1-CREB1 fusions have also been reported in clear cell sarcoma-like tumors of the gastrointestinal tract and other soft tissue neoplasms. ### 4.3 CREB1 Expression Alterations in Solid Tumors Beyond gene fusions, dysregulated CREB1 expression and activity contribute to the pathogenesis of numerous solid tumors: **Breast Cancer**: CREB1 is overexpressed in a subset of breast cancers and promotes tumor progression, metastasis, and therapy resistance. The CREB1/Lin28/miR-638/VASP interactive network drives breast cancer development. CREB1 also regulates tumor dormancy and recurrence in estrogen receptor-positive (ER+) breast cancer, with CREB1 reactivation correlating with dormancy exit and resistance to endocrine therapy. Cullin-5 deficiency promotes mammary tumor development through CREB1-CCL2 signaling. Additionally, the lncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis, and ASCL1 inhibition increases paclitaxel sensitivity by activating ferroptosis via the CREB1/GPX4 axis. **Colorectal Cancer (CRC)**: CREB1 contributes to colorectal cancer cell plasticity by regulating lncRNA CCAT1 and NF-κB pathways. The circular RNA hsa_circ_0079993 acts as an oncogene in CRC through the microRNA-203a-3p.1 and CREB1 axis. A comprehensive bioinformatic analysis revealed a strong cancer relevance of CREB1-regulated genes, with CREB1 target genes being significantly enriched in cancer-related pathways. **Gastric Cancer (GC)**: The lncRNA SNHG4 enhances gastric cancer progression by modulating the miR-409-3p/CREB1 axis. Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression. miR-145-3p regulates gastric cancer progression via targeting CREB1. **Prostate Cancer**: CREB1 plays a critical role in castration-resistant prostate cancer (CRPC). Convergent CREB1/FoxA1 transcriptional activity defines the CRPC gene expression profile. Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST. Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells. **Thyroid Cancer**: CAFs-released exosomal CREB1 promotes cell progression and immune evasion in thyroid cancer via the positive regulation of CCL20. LINC02454 promotes thyroid carcinoma progression via upregulating HMGA2 through CREB1. **Esophageal Cancer**: Direct targeting of CREB1 with imperatorin inhibits TGFβ2-ERK signaling to suppress esophageal cancer metastasis. **Glioblastoma**: CREB1-induced miR-1204 promotes the malignant phenotype of glioblastoma through targeting NR3C2. miR-26-3p regulates proliferation, migration, invasion, and apoptosis of glioma cells by targeting CREB1. **Bladder Cancer**: Circular RNA hsa_circ_0075828 promotes bladder cancer cell proliferation through activation of CREB1. **Non-Small Cell Lung Cancer (NSCLC)**: miR-125b-5p upregulation by TRIM28 induces cisplatin resistance in NSCLC through CREB1 inhibition. ### 4.4 CREB1 in Hematological Malignancies **Multiple Myeloma (MM)**: CREB1 sustains multiple myeloma cell survival by regulating stress tolerance. CREB1 promotes immune escape of MM cells by inducing HLA-E, which inhibits NK cell-mediated cytotoxicity. ### 4.5 CREB1 in Non-Neoplastic Diseases **Osteoarthritis (OA)**: Meta-analysis of GLP1R, GIPR, ADCY3, and CREB1 expression in osteoarthritis identifies CREB1 as a potential biomarker and therapeutic target. DSCR1-1 attenuates OA-associated chondrocyte injury by regulating the CREB1/ALDH2/Wnt/β-catenin axis. Silencing SGK1 alleviates osteoarthritis through epigenetic regulation of CREB1 and ABCA1 expression. **Liver Fibrosis**: ISG15 deficiency in hepatic stellate cells promotes TGFβ2-induced liver fibrosis by counteracting CREB1 ISGylation. **Atrial Fibrillation**: miR-425-5p is negatively associated with atrial fibrosis and promotes atrial remodeling by targeting CREB1 in atrial fibrillation. **Vascular Dementia**: CREB1 gene silencing affects cognitive dysfunction by mediating the PKA-CREB signaling pathway in mice with vascular dementia. **Cerebral Ischemia-Reperfusion Injury**: Aspartame exacerbates cerebral ischemia-reperfusion injury via mitochondrial dysfunction and ERK/CREB1 pathway suppression. Neuregulin-1-mediated neuroprotection following ischemic stroke involves upregulation of CREB1 and FOXO1 transcription factor pathways. **Thyroid Function**: Interaction of fluoride exposure and CREB1 gene polymorphisms affects thyroid function in school-age children. **Polycystic Ovary Syndrome (PCOS)**: MicroRNA-27a-3p affects estradiol and androgen imbalance by targeting Creb1 in granulosa cells in a mouse PCOS model. **Ovarian Aging**: CREB1 is a key regulator in senescent granulosa cells. **Pulmonary Disease**: Sex-dependent regulation of mucin gene transcription and goblet cell secretion machinery following intra-airway IL-13 in mice with conditional loss of club cell Creb1. CREB1 controls mitochondrial dysfunction in 1-nitropyrene-mediated apoptosis of human bronchial cells and lung injury. **Chronic Obstructive Pulmonary Disease (COPD)**: Remote regulation of rs80245547 and rs72673891 mediated by transcription factors C-Jun and CREB1 affects GSTCD expression. **Graft-versus-Host Disease (GVHD)**: Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for GVHD via the CREB1-NRF2 pathway. **Sheep Body Morphometric Traits**: An insertion/deletion within the *CREB1* gene is associated with sheep body morphometric traits, highlighting the conserved role of CREB1 in growth regulation. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions **HIV-1**: CREB1 plays a significant role in the immune response to HIV-1 vaccination. A study by Tomalka et al. (2021) demonstrated that the transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. The recombinant canarypox vector ALVAC, when combined with alum adjuvant, induces CREB1 and its target genes, which augments immunogenicity in non-human primates. This finding suggests that CREB1 activation is a critical determinant of vaccine efficacy and could be targeted to improve HIV-1 vaccine design. **Other Viral Pathogens**: CREB1 is a downstream target of multiple viral signaling pathways. Several viruses, including adenoviruses, hepatitis B virus (HBV), and human papillomavirus (HPV), have been shown to modulate CREB1 activity to promote viral replication and evade host immune responses. For example, the HBV X protein (HBx) activates CREB1-mediated transcription to enhance viral gene expression. However, the specific molecular mechanisms vary depending on the virus and the cellular context. ### 5.2 Bacterial and Parasitic Interactions While direct interactions between bacterial effectors and CREB1 are less well-characterized than viral interactions, CREB1 is involved in host immune responses to bacterial infections. For instance, CREB1 regulates the expression of pro-inflammatory cytokines and antimicrobial peptides in response to bacterial lipopolysaccharide (LPS) stimulation. Additionally, *Mycobacterium tuberculosis* has been shown to modulate CREB1 signaling in macrophages to promote intracellular survival. ### 5.3 Immune Evasion Mechanisms CREB1 contributes to tumor immune evasion through multiple mechanisms. In multiple myeloma, CREB1 induces the expression of HLA-E, a non-classical MHC class I molecule that inhibits NK cell-mediated cytotoxicity by engaging the NKG2A/CD94 inhibitory receptor. In thyroid cancer, CAFs-released exosomal CREB1 promotes immune evasion via the positive regulation of CCL20, which recruits immunosuppressive cells to the tumor microenvironment. In breast cancer, CREB1-CCL2 signaling orchestrates the tumor microenvironment to promote mammary tumor development. These findings highlight CREB1 as a potential target for cancer immunotherapy. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 CREB1 as a Therapeutic Target Given its central role in multiple ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)